Kazia Therapeutics Ltd
KZIA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001075880
No open-market purchases or sales by Kazia Therapeutics Ltd insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $50.7M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Kazia Therapeutics Ltd as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- 0 vs. Q1 2025
- Shares held
- 144.0K
- +113.1K (+366.3%) vs. Q1 2025Converted for a 1-for-5 split
- Total value
- $902.9K
- +$782.0K (+646.8%) vs. Q1 2025
- New holders
- 2
- 2 more added
- Sold out
- 2
- 2 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KZIA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 35 | $50.7M |
| Q1 2026 | 23 | $13.0M |
| Q4 2025 | 22 | $17.1M |
| Q3 2025 | 11 | $1.14M |
| Q2 2025 | 10 | $902.9K |
| Q1 2025 | 10 | $120.9K |
| Q4 2024 | 11 | $569.1K |
| Q3 2024 | 18 | $922.0K |
| Q2 2024 | 11 | $89.5K |
| Q1 2024 | 11 | $115.5K |
| Q4 2023 | 18 | $2.15M |
| Q3 2023 | 10 | $235.9K |
| Q2 2023 | 9 | $327.6K |
| Q1 2023 | 8 | $279.4K |
| Q4 2022 | 10 | $262.0K |
| Q3 2022 | 9 | $527.0K |
| Q2 2022 | 12 | $1.24M |
| Q1 2022 | 12 | $2.90M |
| Q4 2021 | 12 | $4.01M |
| Q3 2021 | 18 | $5.03M |
| Q2 2021 | 15 | $4.35M |
| Q1 2021 | 14 | $4.60M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Kazia Therapeutics Ltd; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Dauntless Investment Group, LLC | 115,769 | $725.9K | 3.41% | +115,769 | New |
| Barclays PLC | 24,000 | $150.5K | 0.00% | 00.0% | UnchangedConverted for a 1-for-5 split |
| UBS Group AG | 3,029 | $19.0K | 0.00% | −2,228−42.4% | ReducedConverted for a 1-for-5 split |
| Rhumbline Advisers | 591 | $3.66K | 0.00% | +209+54.6% | AddedConverted for a 1-for-5 split |
| GAMMA Investing LLC | 265 | $1.66K | 0.00% | 00.0% | UnchangedConverted for a 1-for-5 split |
| SRS Capital Advisors, Inc. | 200 | $1.25K | 0.00% | 00.0% | UnchangedConverted for a 1-for-5 split |
| SBI Securities Co., Ltd. | 100 | $627 | 0.00% | +100 | New |
| MAI Capital Management | 52 | $327 | 0.00% | −719−93.3% | ReducedConverted for a 1-for-5 split |
| Advisor Group Holdings, Inc. | 10 | $62 | 0.00% | 00.0% | UnchangedConverted for a 1-for-5 split |
| Allworth Financial LP | 1 | $7 | 0.00% | +1+400.0% | AddedConverted for a 1-for-5 split |
| Wells Fargo & Company | 0 | $0 | 0.00% | −1−100.0% | Sold outConverted for a 1-for-5 split |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold outConverted for a 1-for-5 split |